These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36275825)

  • 1. Depression in non-alcoholic fatty liver disease is associated with an increased risk of complications and mortality.
    Ng CH; Xiao J; Chew NWS; Chin YH; Chan KE; Quek J; Lim WH; Tan DJH; Loke RWK; Tan C; Tang ASP; Goh XL; Nah B; Syn N; Young DY; Tamaki N; Huang DQ; Siddiqui MS; Noureddin M; Sanyal A; Muthiah M
    Front Med (Lausanne); 2022; 9():985803. PubMed ID: 36275825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease.
    Ng CH; Chan KE; Chin YH; Zeng RW; Tsai PC; Lim WH; Tan DJH; Khoo CM; Goh LH; Ling ZJ; Kulkarni A; Mak LL; Huang DQ; Chan M; Chew NW; Siddiqui MS; Sanyal AJ; Muthiah M
    Clin Mol Hepatol; 2022 Jul; 28(3):565-574. PubMed ID: 35585687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality.
    Ng CH; Wong ZY; Chew NWS; Chan KE; Xiao J; Sayed N; Lim WH; Tan DJH; Loke RWK; Tay PWL; Yong JN; Kong G; Huang DQ; Wang JW; Chan M; Dalakoti M; Tamaki N; Noureddin M; Siddiqui MS; Sanyal AJ; Muthiah M
    Front Cardiovasc Med; 2022; 9():942753. PubMed ID: 36003916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Fatty Liver Associated With Depression? A Meta-Analysis and Systematic Review on the Prevalence, Risk Factors, and Outcomes of Depression and Non-alcoholic Fatty Liver Disease.
    Xiao J; Lim LKE; Ng CH; Tan DJH; Lim WH; Ho CSH; Tan EXX; Sanyal AJ; Muthiah MD
    Front Med (Lausanne); 2021; 8():691696. PubMed ID: 34277666
    [No Abstract]   [Full Text] [Related]  

  • 5. Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease.
    Golabi P; Gerber L; Paik JM; Deshpande R; de Avila L; Younossi ZM
    JHEP Rep; 2020 Dec; 2(6):100171. PubMed ID: 32964202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
    Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
    J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased Risk for Cardiovascular Events in Patients with Diabetic Kidney Disease and Non-Alcoholic Fatty Liver Disease.
    Chinnadurai R; Chrysochou C; Kalra PA
    Nephron; 2019; 141(1):24-30. PubMed ID: 30384370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM
    J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A poor perspective of self weight significantly increases adverse outcomes in non-alcoholic fatty liver disease (NAFLD).
    Fu CE; Ng CH; Chew NWS; Heng ZEQ; Chin YH; Quek J; Lim WH; Xiao J; Chan KE; Tan DJH; Tan C; Zhang S; Koh TK; Nah B; Dan YY; Syn N; Siddiqui MS; Sanyal AJ; Noureddin M; Muthiah M
    Front Med (Lausanne); 2022; 9():977552. PubMed ID: 36250093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of NAFLD with cardiovascular disease and all-cause mortality: a large-scale prospective cohort study based on UK Biobank.
    Ma W; Wu W; Wen W; Xu F; Han D; Lyu J; Huang Y
    Ther Adv Chronic Dis; 2022; 13():20406223221122478. PubMed ID: 36159632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD).
    Golabi P; Stepanova M; Pham HT; Cable R; Rafiq N; Bush H; Gogoll T; Younossi ZM
    BMJ Open Gastroenterol; 2018; 5(1):e000198. PubMed ID: 29607054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease.
    Chinnadurai R; Ritchie J; Green D; Kalra PA
    Nephrol Dial Transplant; 2019 Mar; 34(3):449-457. PubMed ID: 29390103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis.
    Mantovani A; Csermely A; Petracca G; Beatrice G; Corey KE; Simon TG; Byrne CD; Targher G
    Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):903-913. PubMed ID: 34555346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not.
    Younossi ZM; Otgonsuren M; Venkatesan C; Mishra A
    Metabolism; 2013 Mar; 62(3):352-60. PubMed ID: 22999011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD).
    Stepanova M; Rafiq N; Makhlouf H; Agrawal R; Kaur I; Younoszai Z; McCullough A; Goodman Z; Younossi ZM
    Dig Dis Sci; 2013 Oct; 58(10):3017-23. PubMed ID: 23775317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Diabetes Mellitus and All-Cause and Cardiovascular Mortality Among Individuals With Ultrasound-Defined Non-Alcoholic Fatty Liver Disease.
    Wu W; Xiang J; Chen X
    Front Endocrinol (Lausanne); 2021; 12():773342. PubMed ID: 34992579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.
    Targher G; Byrne CD; Lonardo A; Zoppini G; Barbui C
    J Hepatol; 2016 Sep; 65(3):589-600. PubMed ID: 27212244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors.
    Mann JP; Carter P; Armstrong MJ; Abdelaziz HK; Uppal H; Patel B; Chandran S; More R; Newsome PN; Potluri R
    PLoS One; 2020; 15(10):e0241357. PubMed ID: 33108366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-alcoholic fatty liver disease (NAFLD) and the cardiovascular disease (CVD) risk categories in primary care: is there an association?
    Miptah HN; Ramli AS; Mohamad M; Hashim H; Tharek Z
    BMC Fam Pract; 2020 Nov; 21(1):238. PubMed ID: 33218301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.